Meeting
2016 ASCO Annual Meeting
Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.
Authors
Kevin J. Harrington
Royal Marsden Hospital/Institute of Cancer Research, London, United Kingdom
Kevin J. Harrington , Martin David Forster , Magnus Dillon , Lorna Grove , Sola Adeleke , Shuquan Chen , Jane S. Diamond , Henrik Hannus , Kandance Cooper , Jonathan Greenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02633800
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS6104)
DOI
10.1200/JCO.2016.34.15_suppl.TPS6104
Abstract #
TPS6104
Poster Bd #
424b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
First Author: Kevin J. Harrington
Poster
2018 ASCO Annual Meeting
The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients.
First Author: Tony Ng
Poster
2017 ASCO Annual Meeting
Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).
First Author: William Nassib William Jr.
Poster
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
First Author: Makoto Tahara